Bonus 5: 5th annual bone and the oncologist new updates

Current Oncology

Volumn 17, Issue 4, 2010, Pages 113-118

  Bouganim, Nathaniel ^a   Amir, E ^b   Clemons, M ^c  

^a MCGILL UNIVERSITY   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone; Breast cancer; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PLACEBO;

ARTICLE; BONE CANCER; BONE DENSITOMETRY; BONE METASTASIS; BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENE EXPRESSION PROFILING; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; PREDICTION; PROSTATE CANCER;

EID: 78149449834     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i4.691     Document Type: Article

References (7)

1. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: z-fast study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
2. Brufsky A, Bundred N, Coleman R, et al. on behalf of the z-fast and zo-fast Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13:503-14.
3. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11.
4. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13.
5. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the zo-fast Study. Ann Oncol 2010; [Epub ahead of print]
6. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11.
7. Neville-Webbe HL, Coleman RE. Bisphosphonates and rank ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010;46:1211-22.